Released : December 16, 2019 17:25 RNS Number : 0553X MaxCyte, Inc. 16 December 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Director/PCA transaction initial notification Gaithersburg, Maryland - 16 December 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life
Released : December 04, 2019 07:00 RNS Number : 5710V MaxCyte, Inc. 04 December 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ's Adoptive Cell Therapy Programs
Released : November 21, 2019 07:00 RNS Number : 1251U MaxCyte, Inc. 21 November 2019 Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer - Clinical and commercial agreement using MaxCyte's
Released : November 14, 2019 07:00 RNS Number : 3429T MaxCyte, Inc. 14 November 2019 MaxCyte to Present at 2019 Jefferies London Healthcare Conference Gaithersburg, Maryland - 14 November 2019 - MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences company,
Released : November 07, 2019 07:00 RNS Number : 5671S MaxCyte, Inc. 07 November 2019 MaxCyte to Present at BIO-Europe 2019 Gaithersburg, Maryland - 07 November 2019 - MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences company , announces that President and
Released : November 01, 2019 13:04 RNS Number : 0228S MaxCyte, Inc. 01 November 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Result of AGM Gaithersburg, MD - 0 1 November 2019 : MaxCyte (LSE: MXCT, MXCR), the global cell-based therapies and life sciences company, announces that at
Released : October 24, 2019 07:00 RNS Number : 9395Q MaxCyte, Inc. 24 October 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Advances Phase I Clinical Trial of Lead CARMA™ mRNA-based Cell Therapy to Third Cohort of Patients MCY-M11 is being evaluated in relapsed/refractory
Released : October 23, 2019 07:01 RNS Number : 8257Q MaxCyte, Inc. 23 October 2019 MaxCyte Announces Presentations at 5th Annual Cell & Gene Therapy Congress Highlighting Unique Promise of Its Technology Gaithersburg, Maryland - 23 October 2019 - MaxCyte (LSE: MXCT, MXCS), the global
Gaithersburg, Maryland – October 15, 2019: MaxCyte, the global cell-based therapies and life sciences company, announces its planned participation at the BIO Investor Forum in San Francisco, California. CEO & President Doug Doerfler will present 22 October at 11:15 a.m.
Released : October 08, 2019 07:00 RNS Number : 0594P MaxCyte, Inc. 08 October 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Notification of Annual General Meeting and Declaration of Audit Remuneration Gaithersburg, MD - 08 October 2019: MaxCyte (LSE: MXCT, MXCR), the global
